A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
-
Thomas F. Delaney, M.D.
-
David P. Ryan, M.D.
-
Vikram Deshpande, M.B.,B.S.
-
Yves Boucher, Ph.D.
-
Jennifer Yon-Li Wo, M.D.
-
Andrew Xiuxuan Zhu, Ph.D., M.D.
-
Theodore Sunki Hong, M.D.
-
Jeffrey William Clark, M.D.
-
Rakesh K. Jain, Ph.D.
-
Carlos F. Fernandez-Del Castillo, M.D.
-
Harvey Jay Mamon, M.D., Ph.D.
-
Lawrence Scott Blaszkowsky, M.D.
-
Dan Gabriel Duda, Ph.D., D.M.D.
-
Cristina Rosa Ferrone, M.D.
-
Beow Yong Yeap, Sc.D.